Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Passive immunization against phosphorylated tau improves features of Huntington's disease pathology

17 Jan 2022

Abstract excerpt

Huntington's disease is classically described as a neurodegenerative disorder of monogenic aetiology. The disease is characterized by an abnormal polyglutamine expansion in the huntingtin gene, which drives the toxicity of the mutated form of the protein. However, accumulation of the microtubule-associated protein tau, which is involved in a number of neurological disorders, has also been observed in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Neurodegenerative Diseases
Share to Mitochondrial Function and Pathology
Share to Neurological disorders and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35051614
DOI: 10.1016/j.ymthe.2022.01.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Passive immunization against phosphorylated tau improves features of Huntington's disease pathologyPMID 35051614Read ↗

Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy ModelsSemantic proximity Read ↗

Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific AntibodiesSemantic proximity Read ↗

Tau‐targeting passive immunization modulates aspects of pathology in tau transgenic miceSemantic proximity Read ↗

Early detection of exon 1 huntingtin aggregation in zQ175 brains by molecular and histological approachesSemantic proximity Read ↗

Proteostasis as a fundamental principle of Tau immunotherapySemantic proximity Read ↗

Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative PhenotypesSemantic proximity Read ↗

AAV-mediated Expression of a Novel Conformational Anti-Aggregated α-Synuclein Antibody Prolongs Survival in a Genetic Model of α-SynucleinopathiesSemantic proximity Read ↗

Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington’s diseaseSemantic proximity Read ↗

Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.Semantic proximity Read ↗

Development of novel bioassays to detect soluble and aggregated Huntingtin proteins on three technology platformsSemantic proximity Read ↗

DNA Vaccination Target on Amyloid Oligomer also Reduce tau Pathology and Improve Synaptic Function in Aged 3xTg-AD MiceSemantic proximity Read ↗

Enhancing the detection of HTT1a with neoepitope antibodies in mouse models of Huntington’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.